Lack of appropriate testing remains a barrier for patients eligible for targeted treatment
A well-prepared team meets the distinctive needs of patients at hereditary high risk
Findings support need for personalized disease management
Pathogenic POLE/POLD1 mutations lead to improved response to immune checkpoint blockade therapy
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Patients with genetic mutation need more than ocular treatment
Second case ever reported highlights complexity, rarity
A breakthrough in understanding peripartum cardiomyopathy
Cleveland Clinic researchers contradict notion that most adult myeloid neoplasms occur sporadically